Navco Pharmaceuticals (TSXV:NAV) Cash-to-Debt : N/A (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Navco Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2023 was N/A.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Navco Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

During the past 4 years, Navco Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

TSXV:NAV's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.94
* Ranked among companies with meaningful Cash-to-Debt only.

Navco Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Navco Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Navco Pharmaceuticals Cash-to-Debt Chart

Navco Pharmaceuticals Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Cash-to-Debt

No Debt

Navco Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash-to-Debt	Get a 7-Day Free Trial														No Debt	No Debt	No Debt	N/A	N/A

Competitive Comparison of Navco Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Navco Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's Cash-to-Debt falls into.

Navco Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Navco Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2021 is calculated as:

Navco Pharmaceuticals had no debt ⁽¹⁾.

Navco Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Navco Pharmaceuticals (TSXV:NAV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Navco Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Navco Pharmaceuticals (TSXV:NAV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7

Website

Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.